FIELD: pharmaceuticals.
SUBSTANCE: invention relates to antibodies and antigen-binding fragments thereof, which specifically bind to IL-33, as well as to a plasmid for producing an antibody or antigen-binding fragment thereof, to an isolated nucleic acid molecule encoding the antibody or antigen-binding fragment thereof, to a nucleic acid molecule encoding the antibody or antigen-binding fragment thereof, to an expression vector, containing a nucleic acid molecule, to a host cell for producing an antibody or antigen-binding fragment thereof, method of producing an antibody or antigen-binding fragment thereof, a pharmaceutical composition and a method of treating.
EFFECT: antibodies against IL-33, compositions, methods and their application are offered.
21 cl, 3 dwg, 44 tbl, 29 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW FORM OF IL33, MUTATED FORMS OF IL33, ANTIBODIES, ANALYZES AND METHODS OF USING THEM | 2016 |
|
RU2736299C2 |
| ANTIBODIES AGAINST CXCR5, THEIR COMPOSITIONS AND USE | 2018 |
|
RU2798422C2 |
| ANTIBODIES TO CD70 | 2012 |
|
RU2604196C2 |
| ANTIBODIES SPECIFIC FOR LIGAND 1A, SIMILAR TO TUMOR NECROSIS FACTOR, AND THEIR COMPOSITIONS AND APPLICATION | 2014 |
|
RU2708140C1 |
| BINDING MOLECULES SPECIFIC TO IL-21, AND FIELD OF APPLICATION THEREOF | 2015 |
|
RU2708336C2 |
| HUMAN IL-13 ANTIBODY MOLECULES | 2004 |
|
RU2387667C2 |
| ANTI-IL-1R1 BINDING MEMBERS | 2009 |
|
RU2555532C2 |
| ANTI-αvβ8 ANTIBODIES AND COMPOSITIONS AND THEIR USE | 2019 |
|
RU2812478C2 |
| ANTIBODIES TO FACTOR XI AND METHODS OF THEIR APPLICATION | 2016 |
|
RU2739946C2 |
| METHOD FOR GM-CSFRα INHIBITION IN PATIENT | 2012 |
|
RU2639546C2 |
